Medicines Produced In Space Will Soon Have A Path To UK Clinics
On 29th June, the UK announced steps to support making innovative medicines in microgravity. The Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Space Agency have published the first dedicated regulatory pathway for medicines produced in space. A joint statement from the UK Space Agency, MHRA, Regulatory Innovation Office, and the Civil Aviation Authority outlines a coordinated approach to in-orbit pharmaceutical manufacturing. It also sets out how the regulators plan to work together as space-based production develops.
MHRA, drawing on its experience with new regulatory methods—including a 2025 framework for decentralised and modular manufacturing—will adapt its model for medicines created in microgravity and other emerging production environments. The agency is collaborating with the UK Space Agency and researchers to map how these medicines should be regulated and to prepare for potential future production settings. In short, the aim is to align the regulatory process with space-based manufacturing and related technologies.
In-orbit servicing, assembly, and manufacturing is one of four ministerial space priorities focused on driving economic growth. The MHRA and the UK Space Agency are jointly building a regulatory roadmap, due to be published in Autumn 2026. The plan outlines regulatory expectations for manufacturing in space and uses a generic end-to-end model to connect each stage of in-orbit production with existing UK rules. The goal is to help developers by clarifying requirements, noting where rules overlap or are uncertain, and pointing researchers toward compliant pathways.
Microgravity offers unique advantages for drug development. In microgravity, some processes occur more slowly or differently. This can lead to better drug formulations, such as options that are easier to administer outside hospital settings. It can also improve the quality of protein crystals and support advanced therapies, including organ-like systems and tissue models used in cancer research. Discoveries in space could also improve how drugs are made and delivered on Earth.
Evidence from almost 500 biopharma experiments on the International Space Station suggests strong potential for innovation in drug development. Early adopters may gain a leadership position in new manufacturing methods, while clearer regulatory paths from the MHRA and UK Space Agency will provide greater certainty. Space-based insights may also improve efficiency and reduce costs in earthbound manufacturing and delivery methods.
Regulatory progress aligns with the growing commercial space sector. The increased number of launch providers and orbital services, such as SpaceX, Blue Origin, and new European players, has lowered costs and expanded opportunities for routine space experiments. Access to microgravity now includes the International Space Station, commercial platforms, and new orbital labs. Market estimates indicate space-enabled pharmaceutical development could reach several billion dollars in revenue as capabilities mature and successful results accumulate.
The MHRA’s experience with decentralised manufacture and point-of-care regulation informs this effort. The agency has built expertise in regulating advanced therapies in constrained environments and remote oversight. Initiatives like the Regulatory Advice Service for Regenerative Medicine have shown how early, structured engagement with innovators helps shape regulatory approaches, an approach now extending to in-orbit manufacturing. Practically, MHRA is engaging with biopharma firms, space-platform providers, and engineering biology researchers to provide early guidance on development, manufacturing models, and evidentiary needs. It is assessing how GMP, quality, and GDP frameworks apply to in-orbit production, using risk-based methods for novel factors such as space environment and payload logistics. Partners are also exploring adaptive mechanisms to test and refine new concepts in controlled settings before full regulatory submissions.
Internationally, the UK is helping shape norms for space-enabled biopharmaceutical manufacturing. This includes bilateral and multilateral work, such as the UK-Swiss Microgravity Dialogue held in June 2026, which brings together space and pharmaceutical leaders to identify challenges and solutions. This coordinated approach positions the UK to influence international standards, regulatory thinking, and best practices for space-based biomedical research and manufacturing. This aims to provide regulatory clarity, encourage alignment, and support investment in microgravity opportunities.
